-
1
-
-
79957681766
-
Sources of variability in measurements of cardiac troponin T in a community-based sample: The atherosclerosis risk in communities study
-
Agarwal SK,Avery CL, Ballantyne CM, Catellier D, Nambi V, Saunders J, Sharrett AR, Coresh J, Heiss G, Hoogeveen RC. Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study. Clin Chem 2011;57:891-897
-
(2011)
Clin Chem
, vol.57
, pp. 891-897
-
-
Agarwal Skavery, C.L.1
Ballantyne, C.M.2
Catellier, D.3
Nambi, V.4
Saunders, J.5
Sharrett, A.R.6
Coresh, J.7
Heiss, G.8
Hoogeveen, R.C.9
-
2
-
-
84859184996
-
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis
-
Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM Jr, Ridker PM, Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302-1309
-
(2012)
JAMA
, vol.307
, pp. 1302-1309
-
-
Boekholdt, S.M.1
Arsenault, B.J.2
Mora, S.3
Pedersen, T.R.4
LaRosa, J.C.5
Nestel, P.J.6
Simes, R.J.7
Durrington, P.8
Hitman, G.A.9
Welch, K.M.10
DeMicco, D.A.11
Zwinderman, A.H.12
Clearfield, M.B.13
Downs, J.R.14
Tonkin, A.M.15
Colhoun, H.M.16
Gotto, A.M.17
Ridker, P.M.18
Kastelein, J.J.19
-
3
-
-
79959694696
-
A meta-analysis of low-density lipoprotein cholesterol, non-highdensity lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
-
Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-highdensity lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337-345
-
(2011)
Circ Cardiovasc Qual Outcomes
, vol.4
, pp. 337-345
-
-
Sniderman, A.D.1
Williams, K.2
Contois, J.H.3
Monroe, H.M.4
McQueen, M.J.5
De Graaf, J.6
Furberg, C.D.7
-
4
-
-
26244432388
-
Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
-
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, SourjinaT, Peto R, Collins R, Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-1278
-
(2005)
Lancet
, vol.366
, pp. 1267-1278
-
-
Baigent, C.1
Keech, A.2
Kearney, P.M.3
Blackwell, L.4
Buck, G.5
Pollicino, C.6
Kirby, A.7
Sourjinat Peto, R.8
Collins, R.9
Simes, R.10
-
5
-
-
33746494465
-
Low density lipoprotein cholesterol, statins and cardiovascular events: A meta-analysis
-
Genser B, Marz W. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol 2006;95:393-404
-
(2006)
Clin Res Cardiol
, vol.95
, pp. 393-404
-
-
Genser, B.1
Marz, W.2
-
6
-
-
77749310839
-
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia
-
Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010;55:1121-1126
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 1121-1126
-
-
Avis, H.J.1
Hutten, B.A.2
Gagne, C.3
Langslet, G.4
McCrindle, B.W.5
Wiegman, A.6
Hsia, J.7
Kastelein, J.J.8
Stein, E.A.9
-
7
-
-
0038394566
-
Precursor convertases in the secretory pathway, cytosol and extracellular milieu
-
Seidah NG, Prat A. Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 2002;38:79-94
-
(2002)
Essays Biochem
, vol.38
, pp. 79-94
-
-
Seidah, N.G.1
Prat, A.2
-
8
-
-
0037417807
-
The secretory proprotein convertase neural apoptosisregulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation
-
Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosisregulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003;100:928-933
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 928-933
-
-
Seidah, N.G.1
Benjannet, S.2
Wickham, L.3
Marcinkiewicz, J.4
Jasmin, S.B.5
Stifani, S.6
Basak, A.7
Prat, A.8
Chretien, M.9
-
9
-
-
10744230230
-
Functional characterization of Narc 1, a novel proteinase related to proteinase K
-
Naureckiene S, Ma L, Sreekumar K, Purandare U, Lo CF, Huang Y, Chiang LW, Grenier JM, Ozenberger BA, Jacobsen JS, Kennedy JD, DiStefano PS, Wood A, Bingham B. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 2003;420:55-67
-
(2003)
Arch Biochem Biophys
, vol.420
, pp. 55-67
-
-
Naureckiene, S.1
Ma, L.2
Sreekumar, K.3
Purandare, U.4
Lo, C.F.5
Huang, Y.6
Chiang, L.W.7
Grenier, J.M.8
Ozenberger, B.A.9
Jacobsen, J.S.10
Kennedy, J.D.11
DiStefano, P.S.12
Wood, A.13
Bingham, B.14
-
10
-
-
10344253854
-
NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
-
Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, Trillard M, Abifadel M, Tebon A, Attie AD, Rader DJ, Boileau C, Brissette L, Chretien M, Prat A, Seidah NG. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004;279: 48865-48875
-
(2004)
J Biol Chem
, vol.279
, pp. 48865-48875
-
-
Benjannet, S.1
Rhainds, D.2
Essalmani, R.3
Mayne, J.4
Wickham, L.5
Jin, W.6
Asselin, M.C.7
Hamelin, J.8
Varret, M.9
Allard, D.10
Trillard, M.11
Abifadel, M.12
Tebon, A.13
Attie, A.D.14
Rader, D.J.15
Boileau, C.16
Brissette, L.17
Chretien, M.18
Prat, A.19
Seidah, N.G.20
more..
-
11
-
-
34247605063
-
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
-
Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, Mansour MN, McGrath KM, Seddon AP, Shenolikar S, Stutzman-Engwall KJ, Warren LC, Xia D, Qiu X. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007;14:413-419
-
(2007)
Nat Struct Mol Biol
, vol.14
, pp. 413-419
-
-
Cunningham, D.1
Danley, D.E.2
Geoghegan, K.F.3
Griffor, M.C.4
Hawkins, J.L.5
Subashi, T.A.6
Varghese, A.H.7
Ammirati, M.J.8
Culp, J.S.9
Hoth, L.R.10
Mansour, M.N.11
McGrath, K.M.12
Seddon, A.P.13
Shenolikar, S.14
Stutzman-Engwall, K.J.15
Warren, L.C.16
Xia, D.17
Qiu, X.18
-
12
-
-
0037603589
-
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
-
Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-156
-
(2003)
Nat Genet
, vol.34
, pp. 154-156
-
-
Abifadel, M.1
Varret, M.2
Rabes, J.P.3
Allard, D.4
Ouguerram, K.5
Devillers, M.6
Cruaud, C.7
Benjannet, S.8
Wickham, L.9
Erlich, D.10
Derre, A.11
Villeger, L.12
Farnier, M.13
Beucler, I.14
Bruckert, E.15
Chambaz, J.16
Chanu, B.17
Lecerf, J.M.18
Luc, G.19
Moulin, P.20
Weissenbach, J.21
Prat, A.22
Krempf, M.23
Junien, C.24
Seidah, N.G.25
Boileau, C.26
more..
-
13
-
-
29944443017
-
Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia
-
Allard D,Amsellem S, AbifadelM, Trillard M, DevillersM, Luc G, Krempf M, ReznikY, Girardet JP, Fredenrich A, Junien C, Varret M, Boileau C, Benlian P, Rabes JP. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005;26:497
-
(2005)
Hum Mutat
, vol.26
, pp. 497
-
-
Allard Damsellem, S.1
Abifadel, M.2
Trillard, M.3
Devillers, M.4
Luc, G.5
Krempf, M.6
Reznik, Y.7
Girardet, J.P.8
Fredenrich, A.9
Junien, C.10
Varret, M.11
Boileau, C.12
Benlian, P.13
Rabes, J.P.14
-
14
-
-
33344474328
-
Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolæmia: Relationship with plasma lipid traits, heart disease risk and utility in relative tracing
-
Humphries SE, Cranston T, Allen M, Middleton-Price H, Fernandez MC, Senior V, Hawe E, Iversen A, Wray R, Crook MA, Wierzbicki AS. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolæmia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med (Berl) 2006;84:203-214
-
(2006)
J Mol Med (Berl)
, vol.84
, pp. 203-214
-
-
Humphries, S.E.1
Cranston, T.2
Allen, M.3
Middleton-Price, H.4
Fernandez, M.C.5
Senior, V.6
Hawe, E.7
Iversen, A.8
Wray, R.9
Crook, M.A.10
Wierzbicki, A.S.11
-
15
-
-
17144363236
-
Proprotein convertase subtilisin kexin 9: The third locus implicated in autosomal dominant hypercholesterolemia
-
Maxwell KN, Breslow JL. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol 2005; 16:167-172
-
(2005)
Curr Opin Lipidol
, vol.16
, pp. 167-172
-
-
Maxwell, K.N.1
Breslow, J.L.2
-
16
-
-
33749025102
-
Genetic causes of familial hypercholesterolæmia in patients in the UK: Relation to plasma lipid levels and coronary heart disease risk
-
Simon Broome Familial Hyperlipidæmia Register Group and Scientific Steering Committee
-
Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA. Simon Broome Familial Hyperlipidæmia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolæmia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943-949
-
(2006)
J Med Genet
, vol.43
, pp. 943-949
-
-
Humphries, S.E.1
Whittall, R.A.2
Hubbart, C.S.3
Maplebeck, S.4
Cooper, J.A.5
Soutar, A.K.6
Naoumova, R.7
Thompson, G.R.8
Seed, M.9
Durrington, P.N.10
Miller, J.P.11
Betteridge, D.J.12
Neil, H.A.13
-
17
-
-
13944265645
-
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
-
Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37:161-165
-
(2005)
Nat Genet
, vol.37
, pp. 161-165
-
-
Cohen, J.1
Pertsemlidis, A.2
Kotowski, I.K.3
Graham, R.4
Garcia, C.K.5
Hobbs, H.H.6
-
18
-
-
33645103550
-
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
-
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354: 1264-1272
-
(2006)
N Engl J Med
, vol.354
, pp. 1264-1272
-
-
Cohen, J.C.1
Boerwinkle, E.2
Mosley, T.H.3
Hobbs, H.H.4
-
19
-
-
77953309816
-
PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses
-
Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010;55:2833-2842
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2833-2842
-
-
Benn, M.1
Nordestgaard, B.G.2
Grande, P.3
Schnohr, P.4
Tybjærg-Hansen, A.5
-
20
-
-
34447299120
-
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
-
Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007;193:445-448
-
(2007)
Atherosclerosis
, vol.193
, pp. 445-448
-
-
Hooper, A.J.1
Marais, A.D.2
Tanyanyiwa, D.M.3
Burnett, J.R.4
-
21
-
-
71849105837
-
Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: The Coronary Artery Risk Development in Young Adults Study
-
Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E, Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet 2009;2:354-361
-
(2009)
Circ Cardiovasc Genet
, vol.2
, pp. 354-361
-
-
Huang, C.C.1
Fornage, M.2
Lloyd-Jones, D.M.3
Wei, G.S.4
Boerwinkle, E.5
Liu, K.6
-
22
-
-
57649193160
-
Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease
-
Atherosclerosis Risk in Communities (ARIC) Study Investigators
-
Folsom AR, Peacock JM, Boerwinkle E, Atherosclerosis Risk in Communities (ARIC) Study Investigators. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis 2009;202:211-215
-
(2009)
Atherosclerosis
, vol.202
, pp. 211-215
-
-
Folsom, A.R.1
Peacock, J.M.2
Boerwinkle, E.3
-
23
-
-
73849114174
-
PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia
-
Cariou B, Ouguerram K, ZairY, Guerois R, Langhi C, Kourimate S, Benoit I, Le MayC, Gayet C, Belabbas K, Dufernez F, Chetiveaux M, Tarugi P, Krempf M, Benlian P, Costet P. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2009;29: 2191-2197
-
(2009)
Arterioscler Thromb Vasc Biol
, vol.29
, pp. 2191-2197
-
-
Cariou, B.1
Ouguerram, K.2
Zairy Guerois, R.3
Langhi, C.4
Kourimate, S.5
Benoit, I.6
Le Mayc Gayet, C.7
Belabbas, K.8
Dufernez, F.9
Chetiveaux, M.10
Tarugi, P.11
Krempf, M.12
Benlian, P.13
Costet, P.14
-
24
-
-
33748661502
-
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
-
Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, Cohen JC, Hobbs HH. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006;79:514-523
-
(2006)
Am J Hum Genet
, vol.79
, pp. 514-523
-
-
Zhao, Z.1
Tuakli-Wosornu, Y.2
Lagace, T.A.3
Kinch, L.4
Grishin, N.V.5
Horton, J.D.6
Cohen, J.C.7
Hobbs, H.H.8
-
25
-
-
67649834056
-
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
-
Chan JC, Piper DE, Cao Q, Liu D, King C,WangW, Tang J, Liu Q, Higbee J, Xia Z, DiY, Shetterly S, Arimura Z, Salomonis H, Romanow WG, Thibault ST, Zhang R, Cao P, YangXP, Yu T, LuM, RetterMW, Kwon G, Henne K, Pan O, Tsai MM, Fuchslocher B, Yang E, Zhou L, Lee KJ, Daris M, Sheng J, Wang Y, Shen WD, Yeh WC, Emery M, Walker NP, Shan B, Schwarz M, Jackson SM. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009;106:9820-9825
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 9820-9825
-
-
Chan, J.C.1
Piper, D.E.2
Cao, Q.3
Liu, D.4
King, C.5
Wang, W.6
Tang, J.7
Liu, Q.8
Higbee, J.9
Xia, Z.10
Diy Shetterly, S.11
Arimura, Z.12
Salomonis, H.13
Romanow, W.G.14
Thibault, S.T.15
Zhang, R.16
Cao, P.17
Yangxp Yu, T.18
Rettermw, L.19
Kwon, G.20
Henne, K.21
Pan, O.22
Tsai, M.M.23
Fuchslocher, B.24
Yang, E.25
Zhou, L.26
Lee, K.J.27
Daris, M.28
Sheng, J.29
Wang, Y.30
Shen, W.D.31
Yeh, W.C.32
Emery, M.33
Walker, N.P.34
Shan, B.35
Schwarz, M.36
Jackson, S.M.37
more..
-
26
-
-
84863116753
-
An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes
-
Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, WangW, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci 2012;8:310-327
-
(2012)
Int J Biol Sci
, vol.8
, pp. 310-327
-
-
Zhang, L.1
McCabe, T.2
Condra, J.H.3
Ni, Y.G.4
Peterson, L.B.5
Wang, W.6
Strack, A.M.7
Wang, F.8
Pandit, S.9
Hammond, H.10
Wood, D.11
Lewis, D.12
Rosa, R.13
Mendoza, V.14
Cumiskey, A.M.15
Johns, D.G.16
Hansen, B.C.17
Shen, X.18
Geoghagen, N.19
Jensen, K.20
Zhu, L.21
Wietecha, K.22
Wisniewski, D.23
Huang, L.24
Zhao, J.Z.25
Ernst, R.26
Hampton, R.27
Haytko, P.28
Ansbro, F.29
Chilewski, S.30
Chin, J.31
Mitnaul, L.J.32
Pellacani, A.33
Sparrow, C.P.34
An, Z.35
Strohl, W.36
Hubbard, B.37
Plump, A.S.38
Blom, D.39
Sitlani, A.40
more..
-
27
-
-
78650904300
-
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
-
Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, Wang F, Pandit S, Hammond HA, Rosa R, Cummings RT, Wood DD, Liu X, Bottomley MJ, Shen X, Cubbon RM, Wang SP, Johns DG, Volpari C, Hamuro L, Chin J, Huang L, Zhao JZ, Vitelli S, Haytko P, Wisniewski D, Mitnaul LJ, Sparrow CP, Hubbard B, Carfi A, Sitlani A. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 2011;52:78-86
-
(2011)
J Lipid Res
, vol.52
, pp. 78-86
-
-
Ni, Y.G.1
Di Marco, S.2
Condra, J.H.3
Peterson, L.B.4
Wang, W.5
Wang, F.6
Pandit, S.7
Hammond, H.A.8
Rosa, R.9
Cummings, R.T.10
Wood, D.D.11
Liu, X.12
Bottomley, M.J.13
Shen, X.14
Cubbon, R.M.15
Wang, S.P.16
Johns, D.G.17
Volpari, C.18
Hamuro, L.19
Chin, J.20
Huang, L.21
Zhao, J.Z.22
Vitelli, S.23
Haytko, P.24
Wisniewski, D.25
Mitnaul, L.J.26
Sparrow, C.P.27
Hubbard, B.28
Carfi, A.29
Sitlani, A.30
more..
-
28
-
-
50149101511
-
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
-
Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Rohl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher HP, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008;105:11915-11920
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 11915-11920
-
-
Frank-Kamenetsky, M.1
Grefhorst, A.2
Anderson, N.N.3
Racie, T.S.4
Bramlage, B.5
Akinc, A.6
Butler, D.7
Charisse, K.8
Dorkin, R.9
Fan, Y.10
Gamba-Vitalo, C.11
Hadwiger, P.12
Jayaraman, M.13
John, M.14
Jayaprakash, K.N.15
Maier, M.16
Nechev, L.17
Rajeev, K.G.18
Read, T.19
Rohl, I.20
Soutschek, J.21
Tan, P.22
Wong, J.23
Wang, G.24
Zimmermann, T.25
De Fougerolles, A.26
Vornlocher, H.P.27
Langer, R.28
Anderson, D.G.29
Manoharan, M.30
Koteliansky, V.31
Horton, J.D.32
Fitzgerald, K.33
more..
-
29
-
-
84892741671
-
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial
-
Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014;383:60-68
-
(2014)
Lancet
, vol.383
, pp. 60-68
-
-
Fitzgerald, K.1
Frank-Kamenetsky, M.2
Shulga-Morskaya, S.3
Liebow, A.4
Bettencourt, B.R.5
Sutherland, J.E.6
Hutabarat, R.M.7
Clausen, V.A.8
Karsten, V.9
Cehelsky, J.10
Nochur, S.V.11
Kotelianski, V.12
Horton, J.13
Mant, T.14
Chiesa, J.15
Ritter, J.16
Munisamy, M.17
Vaishnaw, A.K.18
Gollob, J.A.19
Simon, A.20
more..
-
30
-
-
77956519356
-
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo
-
Gupta N, Fisker N, Asselin MC, Lindholm M, Rosenbohm C, Orum H, Elmen J, Seidah NG, Straarup EM. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE 2010;5:e10682
-
(2010)
PLoS ONE
, vol.5
, pp. e10682
-
-
Gupta, N.1
Fisker, N.2
Asselin, M.C.3
Lindholm, M.4
Rosenbohm, C.5
Orum, H.6
Elmen, J.7
Seidah, N.G.8
Straarup, E.M.9
-
31
-
-
34147136507
-
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
-
Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007;48:763-767
-
(2007)
J Lipid Res
, vol.48
, pp. 763-767
-
-
Graham, M.J.1
Lemonidis, K.M.2
Whipple, C.P.3
Subramaniam, A.4
Monia, B.P.5
Crooke, S.T.6
Crooke, R.M.7
-
32
-
-
84856517940
-
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates
-
LindholmMW, Elmen J, Fisker N, HansenHF, Persson R, Moller MR, Rosenbohm C, Orum H, Straarup EM, Koch T. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 2012;20: 376-381
-
(2012)
Mol Ther
, vol.20
, pp. 376-381
-
-
Lindholmmw Elmen, J.1
Fisker, N.2
Hansenhf Persson, R.3
Moller, M.R.4
Rosenbohm, C.5
Orum, H.6
Straarup, E.M.7
Koch, T.8
-
33
-
-
84872307169
-
PCSK9 Inhibitors: Potential in cardiovascular therapeutics
-
Do RQ, Vogel RA, Schwartz GG. PCSK9 Inhibitors: potential in cardiovascular therapeutics. Curr Cardiol Rep 2013;15:1-12
-
(2013)
Curr Cardiol Rep
, vol.15
, pp. 1-12
-
-
Do, R.Q.1
Vogel, R.A.2
Schwartz, G.G.3
-
34
-
-
34547108600
-
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation
-
Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602-18612
-
(2007)
J Biol Chem
, vol.282
, pp. 18602-18612
-
-
Zhang, D.W.1
Lagace, T.A.2
Garuti, R.3
Zhao, Z.4
McDonald, M.5
Horton, J.D.6
Cohen, J.C.7
Hobbs, H.H.8
-
35
-
-
38349117118
-
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
-
Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008;283:2363-2372
-
(2008)
J Biol Chem
, vol.283
, pp. 2363-2372
-
-
Poirier, S.1
Mayer, G.2
Benjannet, S.3
Bergeron, E.4
Marcinkiewicz, J.5
Nassoury, N.6
Mayer, H.7
Nimpf, J.8
Prat, A.9
Seidah, N.G.10
-
36
-
-
33750597734
-
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
-
Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006;116: 2995-3005
-
(2006)
J Clin Invest
, vol.116
, pp. 2995-3005
-
-
Lagace, T.A.1
Curtis, D.E.2
Garuti, R.3
McNutt, M.C.4
Park, S.W.5
Prather, H.B.6
Anderson, N.N.7
Ho, Y.K.8
Hammer, R.E.9
Horton, J.D.10
-
37
-
-
46349103159
-
Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
-
Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin A, Kowala M, Alborn WE, Konrad RJ, Cao G. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun 2008;370:634-640
-
(2008)
Biochem Biophys Res Commun
, vol.370
, pp. 634-640
-
-
Schmidt, R.J.1
Beyer, T.P.2
Bensch, W.R.3
Qian, Y.W.4
Lin, A.5
Kowala, M.6
Alborn, W.E.7
Konrad, R.J.8
Cao, G.9
-
38
-
-
13844310887
-
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
-
Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 2005;102:2069-2074
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 2069-2074
-
-
Maxwell, K.N.1
Fisher, E.A.2
Breslow, J.L.3
-
39
-
-
17244377696
-
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
-
Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005;102:5374-5379
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 5374-5379
-
-
Rashid, S.1
Curtis, D.E.2
Garuti, R.3
Anderson, N.N.4
Bashmakov, Y.5
Ho, Y.K.6
Hammer, R.E.7
Moon, Y.A.8
Horton, J.D.9
-
40
-
-
34848861377
-
Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol
-
Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007;53:1814-1819
-
(2007)
Clin Chem
, vol.53
, pp. 1814-1819
-
-
Alborn, W.E.1
Cao, G.2
Careskey, H.E.3
Qian, Y.W.4
Subramaniam, D.R.5
Davies, J.6
Conner, E.M.7
Konrad, R.J.8
-
41
-
-
84921262461
-
On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
-
Tavori H, Rashid S, Fazio S. On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 2014;238: 264-270
-
(2014)
Atherosclerosis
, vol.238
, pp. 264-270
-
-
Tavori, H.1
Rashid, S.2
Fazio, S.3
-
42
-
-
84858638369
-
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
-
Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, Du Y, Kranz T, Gasparino E, Swergold GD. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366: 1108-1118
-
(2012)
N Engl J Med
, vol.366
, pp. 1108-1118
-
-
Stein, E.A.1
Mellis, S.2
Yancopoulos, G.D.3
Stahl, N.4
Logan, D.5
Smith, W.B.6
Lisbon, E.7
Gutierrez, M.8
Webb, C.9
Wu, R.10
Du, Y.11
Kranz, T.12
Gasparino, E.13
Swergold, G.D.14
-
43
-
-
84862219022
-
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy
-
McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59: 2344-2353
-
(2012)
J Am Coll Cardiol
, vol.59
, pp. 2344-2353
-
-
McKenney, J.M.1
Koren, M.J.2
Kereiakes, D.J.3
Hanotin, C.4
Ferrand, A.C.5
Stein, E.A.6
-
44
-
-
84870478439
-
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolæmia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study
-
LAPLACE-TIMI 57 Investigators
-
Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS. LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolæmia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380: 2007-2017
-
(2012)
Lancet
, vol.380
, pp. 2007-2017
-
-
Giugliano, R.P.1
Desai, N.R.2
Kohli, P.3
Rogers, W.J.4
Somaratne, R.5
Huang, F.6
Liu, T.7
Mohanavelu, S.8
Hoffman, E.B.9
McDonald, S.T.10
Abrahamsen, T.E.11
Wasserman, S.M.12
Scott, R.13
Sabatine, M.S.14
-
45
-
-
84868206496
-
Effects of AMG 145 on low-density lipoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins
-
Dias CS, Shaywitz AJ,Wasserman SM, Smith BP, Gao B, Stolman DS, Crispino CP, Smirnakis KV, Emery MG, Colbert A, Gibbs JP, Retter MW, Cooke BP, Uy ST, Matson M, Stein EA. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60:1888-1898
-
(2012)
J Am Coll Cardiol
, vol.60
, pp. 1888-1898
-
-
Dias, C.S.1
Shaywitz, A.J.2
Wasserman, S.M.3
Smith, B.P.4
Gao, B.5
Stolman, D.S.6
Crispino, C.P.7
Smirnakis, K.V.8
Emery, M.G.9
Colbert, A.10
Gibbs, J.P.11
Retter, M.W.12
Cooke, B.P.13
Uy, S.T.14
Matson, M.15
Stein, E.A.16
-
46
-
-
84868689211
-
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia
-
Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367: 1891-1900
-
(2012)
N Engl J Med
, vol.367
, pp. 1891-1900
-
-
Roth, E.M.1
McKenney, J.M.2
Hanotin, C.3
Asset, G.4
Stein, E.A.5
-
47
-
-
84899846576
-
A 52-week placebocontrolled trial of evolocumab in hyperlipidemia
-
DESCARTES Investigators
-
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA. DESCARTES Investigators. A 52-week placebocontrolled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370: 1809-1819
-
(2014)
N Engl J Med
, vol.370
, pp. 1809-1819
-
-
Blom, D.J.1
Hala, T.2
Bolognese, M.3
Lillestol, M.J.4
Toth, P.D.5
Burgess, L.6
Ceska, R.7
Roth, E.8
Koren, M.J.9
Ballantyne, C.M.10
Monsalvo, M.L.11
Tsirtsonis, K.12
Kim, J.B.13
Scott, R.14
Wasserman, S.M.15
Stein, E.A.16
-
48
-
-
84900303213
-
Effect of evolocumab or ezetimibe added to moderate- or highintensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial
-
LAPLACE-2 Investigators
-
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R. LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or highintensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311:1870-1882
-
(2014)
JAMA
, vol.311
, pp. 1870-1882
-
-
Robinson, J.G.1
Nedergaard, B.S.2
Rogers, W.J.3
Fialkow, J.4
Neutel, J.M.5
Ramstad, D.6
Somaratne, R.7
Legg, J.C.8
Nelson, P.9
Scott, R.10
Wasserman, S.M.11
Weiss, R.12
-
49
-
-
84906323762
-
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
-
Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014;176:55-61
-
(2014)
Int J Cardiol
, vol.176
, pp. 55-61
-
-
Roth, E.M.1
Taskinen, M.R.2
Ginsberg, H.N.3
Kastelein, J.J.4
Colhoun, H.M.5
Robinson, J.G.6
Merlet, L.7
Pordy, R.8
Baccara-Dinet, M.T.9
-
50
-
-
84892679366
-
Efficacy and safety of longer-termadministration of evolocumab(AMG145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial
-
Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, Civeira F, Somaratne R, Nelson P, Liu T, Scott R,Wasserman SM, Sabatine MS. OSLER Investigators. Efficacy and safety of longer-termadministration of evolocumab(AMG145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014;129: 234-243
-
(2014)
Circulation
, vol.129
, pp. 234-243
-
-
Koren, M.J.1
Giugliano, R.P.2
Raal, F.J.3
Sullivan, D.4
Bolognese, M.5
Langslet, G.6
Civeira, F.7
Somaratne, R.8
Nelson, P.9
Liu, T.10
Scott, R.11
Wasserman, S.M.12
Sabatine, M.S.13
-
51
-
-
84929322473
-
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolæmia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial
-
Colhoun HM. for the ODYSSEY COMBO II Investigators, Feb 16
-
Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. for the ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolæmia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J 2015; Feb 16
-
(2015)
Eur Heart J
-
-
Cannon, C.P.1
Cariou, B.2
Blom, D.3
McKenney, J.M.4
Lorenzato, C.5
Pordy, R.6
Chaudhari, U.7
-
52
-
-
84890461947
-
Familial hypercholesterolæmia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society
-
European Atherosclerosis Society Consensus Panel
-
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolæmia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-3490a
-
(2013)
Eur Heart J
, vol.34
, pp. 3478-3490a
-
-
Nordestgaard, B.G.1
Chapman, M.J.2
Humphries, S.E.3
Ginsberg, H.N.4
Masana, L.5
Descamps, O.S.6
Wiklund, O.7
Hegele, R.A.8
Raal, F.J.9
Defesche, J.C.10
Wiegman, A.11
Santos, R.D.12
Watts, G.F.13
Parhofer, K.G.14
Hovingh, G.K.15
Kovanen, P.T.16
Boileau, C.17
Averna, M.18
Boren, J.19
Bruckert, E.20
Catapano, A.L.21
Kuivenhoven, J.A.22
Pajukanta, P.23
Ray, K.24
Stalenhoef, A.F.25
Stroes, E.26
Taskinen, M.R.27
Tybjærg-Hansen, A.28
more..
-
53
-
-
52049109169
-
Cardiovascular disease in familial hypercholesterolæmia: Influence of low-density lipoprotein receptor mutation type and classic risk factors
-
Spanish Familial Hypercholesterolæmia Group
-
Alonso R, Mata N, Castillo S, Fuentes F, Sænz P, Muniz O, Galiana J, Figueras R, Diaz JL, Gomez-Enterria P, Mauri M, Piedecausa M, Irigoyen L, Aguado R, Mata P. Spanish Familial Hypercholesterolæmia Group. Cardiovascular disease in familial hypercholesterolæmia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008;200:315-321
-
(2008)
Atherosclerosis
, vol.200
, pp. 315-321
-
-
Alonso, R.1
Mata, N.2
Castillo, S.3
Fuentes, F.4
Sænz, P.5
Muniz, O.6
Galiana, J.7
Figueras, R.8
Diaz, J.L.9
Gomez-Enterria, P.10
Mauri, M.11
Piedecausa, M.12
Irigoyen, L.13
Aguado, R.14
Mata, P.15
-
54
-
-
9644287995
-
The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolæmia: Data in 2400 patients
-
Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, van Lennep HW, Sijbrands EJ, Kastelein JJ. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolæmia: data in 2400 patients. J Intern Med 2004;256:482-490
-
(2004)
J Intern Med
, vol.256
, pp. 482-490
-
-
Jansen, A.C.1
Van Aalst-Cohen, E.S.2
Tanck, M.W.3
Trip, M.D.4
Lansberg, P.J.5
Liem, A.H.6
Van Lennep, H.W.7
Sijbrands, E.J.8
Kastelein, J.J.9
-
55
-
-
56349147086
-
Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia
-
Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, Araujo L, Vohra Y, Defesche JC, Wilson JM, Rader DJ. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008;102:1438-1443
-
(2008)
Am J Cardiol
, vol.102
, pp. 1438-1443
-
-
Kolansky, D.M.1
Cuchel, M.2
Clark, B.J.3
Paridon, S.4
McCrindle, B.W.5
Wiegers, S.E.6
Araujo, L.7
Vohra, Y.8
Defesche, J.C.9
Wilson, J.M.10
Rader, D.J.11
-
56
-
-
77049105368
-
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in the Netherlands
-
Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, Abbink EJ, Stalenhoef AF, Visseren FL. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010;209:189-194
-
(2010)
Atherosclerosis
, vol.209
, pp. 189-194
-
-
Pijlman, A.H.1
Huijgen, R.2
Verhagen, S.N.3
Imholz, B.P.4
Liem, A.H.5
Kastelein, J.J.6
Abbink, E.J.7
Stalenhoef, A.F.8
Visseren, F.L.9
-
57
-
-
84874956296
-
Management of familial hypercholesterolemia: A review of the recommendations from the National Lipid Association Expert Panelon Familial Hypercholesterolemia
-
Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panelon Familial Hypercholesterolemia. J Manag Care Pharm 2013;19:139-149
-
(2013)
J Manag Care Pharm
, vol.19
, pp. 139-149
-
-
Robinson, J.G.1
-
58
-
-
2542461241
-
Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal
-
O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J AmColl Cardiol 2004;43:2142-2146
-
(2004)
J AmColl Cardiol
, vol.43
, pp. 2142-2146
-
-
O'Keefe, J.H.1
Cordain, L.2
Harris, W.H.3
Moe, R.M.4
Vogel, R.5
-
59
-
-
84922938167
-
CannonCP.IMPROVE-IT trial: Acomparisonof ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes
-
CannonCP.IMPROVE-IT trial: acomparisonof ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation 2014;130:2105-2126
-
(2014)
Circulation
, vol.130
, pp. 2105-2126
-
-
-
60
-
-
52049116959
-
Clinical characterization and molecular mechanisms of statin myopathy
-
Toth PP, Harper CR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther 2008;6:955-969
-
(2008)
Expert Rev Cardiovasc Ther
, vol.6
, pp. 955-969
-
-
Toth, P.P.1
Harper, C.R.2
Jacobson, T.A.3
-
62
-
-
84937643240
-
Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS i and II
-
Bays H, Farnier M, Gaudet D, Weiss R, Lima Ruiz J, Watts GF, Gouni-Berthold I, Robinson JG, Jones PH, Severance R, Averna M, Steinhagen-Thiessen E, Colhoun HM, Zhao J, Du Y, Hanotin C, Donahue S. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II. Circulation 2014;130:2118-2119
-
(2014)
Circulation
, vol.130
, pp. 2118-2119
-
-
Bays, H.1
Farnier, M.2
Gaudet, D.3
Weiss, R.4
Lima Ruiz, J.5
Watts, G.F.6
Gouni-Berthold, I.7
Robinson, J.G.8
Jones, P.H.9
Severance, R.10
Averna, M.11
Steinhagen-Thiessen, E.12
Colhoun, H.M.13
Zhao, J.14
Du, Y.15
Hanotin, C.16
Donahue, S.17
-
64
-
-
22044444971
-
Total first-year costs of acute coronary syndrome in a managed care setting
-
Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manag Care Pharm 2005;11:300-306
-
(2005)
J Manag Care Pharm
, vol.11
, pp. 300-306
-
-
Etemad, L.R.1
McCollam, P.L.2
-
65
-
-
81055155570
-
Costeffectiveness of the use of low- and high-potency statins in people at low cardiovascular risk
-
Alberta Kidney Disease Network
-
Conly J, Clement F, Tonelli M, Hemmelgarn B, Klarenbach S, Lloyd A, McAlister FA, Husereau D, Wiebe N, Au F, Manns B. Alberta Kidney Disease Network. Costeffectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. CMAJ 2011;183:E1180-8
-
(2011)
CMAJ
, vol.183
, pp. E1180-E1188
-
-
Conly, J.1
Clement, F.2
Tonelli, M.3
Hemmelgarn, B.4
Klarenbach, S.5
Lloyd, A.6
McAlister, F.A.7
Husereau, D.8
Wiebe, N.9
Au, F.10
Manns, B.11
-
67
-
-
74549114679
-
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolæmia
-
Nherera L, Calvert NW, Demott K, Humphries SE, Neil HA, Minhas R, Thorogood M. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolæmia. Curr Med Res Opin 2010;26:529-536
-
(2010)
Curr Med Res Opin
, vol.26
, pp. 529-536
-
-
Nherera, L.1
Calvert, N.W.2
Demott, K.3
Humphries, S.E.4
Neil, H.A.5
Minhas, R.6
Thorogood, M.7
-
68
-
-
84926191670
-
ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
-
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499
-
(2015)
N Engl J Med
, vol.372
, pp. 1489-1499
-
-
Robinson, J.G.1
Farnier, M.2
Krempf, M.3
Bergeron, J.4
Luc, G.5
Averna, M.6
Stroes, E.S.7
Langslet, G.8
Raal, F.J.9
El Shahawy, M.10
Koren, M.J.11
Lepor, N.E.12
Lorenzato, C.13
Pordy, R.14
Chaudhari, U.15
Kastelein, J.J.16
-
69
-
-
84885447918
-
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis
-
Urban D, Pöss J, Böhm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 2013;62:1401-1408
-
(2013)
J Am Coll Cardiol
, vol.62
, pp. 1401-1408
-
-
Urban, D.1
Pöss, J.2
Böhm, M.3
Laufs, U.4
-
70
-
-
84925351969
-
Lipid lowering with PCSK9 inhibitors
-
Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014; 11:563-575
-
(2014)
Nat Rev Cardiol
, vol.11
, pp. 563-575
-
-
Dadu, R.T.1
Ballantyne, C.M.2
-
71
-
-
84939568663
-
Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis
-
Koren MJ, Roth EM, McKenney JM, Gipe D, Hanotin C, Ferrand AC, Wu R, Dufour R. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgrad Med 2015;127:125-132
-
(2015)
Postgrad Med
, vol.127
, pp. 125-132
-
-
Koren, M.J.1
Roth, E.M.2
McKenney, J.M.3
Gipe, D.4
Hanotin, C.5
Ferrand, A.C.6
Wu, R.7
Dufour, R.8
-
72
-
-
84914703551
-
PCSK9 antibodies for the treatment of hypercholesterolemia
-
Gouni-Berthold I, Berthold HK. PCSK9 antibodies for the treatment of hypercholesterolemia. Nutrients 2014;6:5517-5533
-
(2014)
Nutrients
, vol.6
, pp. 5517-5533
-
-
Gouni-Berthold, I.1
Berthold, H.K.2
|